Wire · regulatory
TOP-REAL's Digital Bet: Can eCOA Technology Solve the Toxicity Crisis Killing HER2+ ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
The TOP-REAL study evaluates whether digital monitoring with electronic clinical outcome assessment (eCOA) technology can detect toxicities early enough in HER2-positive metastatic breast cancer patients to reduce treatment discontinuations, addressing a critical issue in real-world use of trastuzumab deruxtecan. The study also challenges current FDA guidance on remote safety monitoring and patient-reported outcomes by aiming to provide evidence for regulatory acceptance of eCOA data in cancer trial safety claims.
This Wire brief sits within Fusion42's coverage of Digital Health and Medtech.
◆ ◆ The Wire takeaway
You face a shift as regulators may soon accept digital symptom tracking to prove treatment safety in cancer trials. That opens a door to build eCOA tools that fill the critical timing gap in toxicity detection and keep patients on key therapies longer.
◆ Coverage
1 source · 22 Nov 2026
◆ Related on Wire
◆ Topics